Pharmaceuticals
Global competitive edge due to integrated and efficient manufacturing operations
We believe our large-scale capacity manufacturing sites in India provide
us with competitive advantages in terms of economies of scale and operating costs as compared to many of our global
competitors. In addition, by the virtue of our integrated operations, we enjoy competitive advantages in the form of
cost efficiencies by producing across the value chain, thereby reducing our dependence on third parties for supply
of starting materials which helps to insulate us from significant volatility in raw materials prices. The APIs from
our manufacturing facility is used for the Solid Dosage Formulations business. Such integration between our Solid
Dosage Formulations and APIs business lines allows us to continuously improve our cost of production. Additionally,
our radiopharmaceutical products are distributed through more than 45 radiopharmacies. We operate our plants in
accordance with cGMP and/or other applicable requirements. We currently operate four US FDA-approved manufacturing
facilities in North America and two US FDA-approved manufacturing facilities in India.